132 related articles for article (PubMed ID: 17911640)
1. Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity.
Weinhold M; Sommermeyer D; Uckert W; Blankenstein T
J Immunol; 2007 Oct; 179(8):5534-42. PubMed ID: 17911640
[TBL] [Abstract][Full Text] [Related]
2. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.
Miller AM; Bahmanof M; Zehn D; Cohen EEW; Schoenberger SP
Cancer Immunol Res; 2019 Jan; 7(1):40-49. PubMed ID: 30482746
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cytokine-driven functional differentiation of CD8 T cells by suppressor of cytokine signaling 1 controls autoimmunity and preserves their proliferative capacity toward foreign antigens.
Ramanathan S; Dubois S; Gagnon J; Leblanc C; Mariathasan S; Ferbeyre G; Rottapel R; Ohashi PS; Ilangumaran S
J Immunol; 2010 Jul; 185(1):357-66. PubMed ID: 20519645
[TBL] [Abstract][Full Text] [Related]
4. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
[TBL] [Abstract][Full Text] [Related]
5. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice.
Otahal P; Schell TD; Hutchinson SC; Knowles BB; Tevethia SS
J Immunol; 2006 Sep; 177(5):3089-99. PubMed ID: 16920946
[TBL] [Abstract][Full Text] [Related]
6. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
8. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
10. Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.
Liu W; Evanoff DP; Chen X; Luo Y
J Immunol; 2007 Jan; 178(1):539-46. PubMed ID: 17182594
[TBL] [Abstract][Full Text] [Related]
11. A spontaneous CD8 T cell-dependent autoimmune disease to an antigen expressed under the human keratin 14 promoter.
McGargill MA; Mayerova D; Stefanski HE; Koehn B; Parke EA; Jameson SC; Panoskaltsis-Mortari A; Hogquist KA
J Immunol; 2002 Aug; 169(4):2141-7. PubMed ID: 12165543
[TBL] [Abstract][Full Text] [Related]
12. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
13. PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.
Wiede F; Ziegler A; Zehn D; Tiganis T
J Autoimmun; 2014 Sep; 53():105-14. PubMed ID: 24997008
[TBL] [Abstract][Full Text] [Related]
14. Self-antigen maintains the innate antibacterial function of self-specific CD8 T cells in vivo.
Dhanji S; Chow MT; Teh HS
J Immunol; 2006 Jul; 177(1):138-46. PubMed ID: 16785508
[TBL] [Abstract][Full Text] [Related]
15. Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response.
Liu Z; Lefrançois L
J Immunol; 2004 Oct; 173(7):4324-30. PubMed ID: 15383561
[TBL] [Abstract][Full Text] [Related]
16. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors.
Gladow M; Uckert W; Blankenstein T
Eur J Immunol; 2004 Jul; 34(7):1882-91. PubMed ID: 15214036
[TBL] [Abstract][Full Text] [Related]
17. An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.
Rausch MP; Hastings KT
PLoS One; 2015; 10(4):e0123332. PubMed ID: 25875653
[TBL] [Abstract][Full Text] [Related]
18. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
19. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
20. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
